The Alarming Statistics
A recent study highlights a troubling situation regarding drug-resistant infections in low- and middle-income countries (LMICs). The research reveals that a mere 7% of carbapenem-resistant Gram-negative (CRGN) bacterial infections receive effective antibiotic treatment. This significant gap in treatment poses a considerable threat to global health and the ongoing battle against antimicrobial resistance (AMR).
The findings from this modelling study underscore the urgent need for improved healthcare access and antibiotic stewardship in these regions. Without adequate treatment options, the burden of drug-resistant infections will continue to escalate, putting countless lives at risk. Addressing this issue is critical for ensuring the effectiveness of current antibiotics and safeguarding public health.
